Inventor · disambiguated record
Thomas P. Maduskuie, Jr.
Also filed as: MADUSKUIE JR THOMAS P · MADUSKUIE JR THOMAS PETER · MADUSKUIE THOMAS P · MADUSKUIE THOMAS P JR
53 granted patents·10 pending applications·1,018 citations·filing 1989–2025
99Inventor score
Files withINCYTE CORP33BRISTOL MYERS SQUIBB PHARMA CO9BRISTOL MYERS SQUIBB CO7DU PONT MERCK PHARMA3DU PONT PHARM CO2
Top patents by PatentIndex Score
63 records- 0199US11059821B21H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteinsINCYTE CORP·Filed 2020·Granted Jul 13, 2021·13 cites·26 claims
- 0299US9938294B2Tricyclic heterocycles as BET protein inhibitorsINCYTE CORP·Filed 2017·Granted Apr 10, 2018·24 cites·14 claims
- 0399US9624241B2Tricyclic heterocycles as BET protein inhibitorsINCYTE CORP·Filed 2015·Granted Apr 18, 2017·27 cites·8 claims
- 0498US10464947B2Tricyclic heterocycles as BET protein inhibitorsINCYTE CORP·Filed 2018·Granted Nov 5, 2019·17 cites·56 claims
- 0598US9540368B21H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteinsINCYTE CORP·Filed 2015·Granted Jan 10, 2017·35 cites·4 claims
- 0698US8415362B2Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitorsRODGERS JAMES D·Filed 2008·Granted Apr 9, 2013·117 cites·21 claims
- 0797US11702416B21H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteinsINCYTE CORP·Filed 2021·Granted Jul 18, 2023·4 cites·19 claims
- 0897US11498926B2Tricyclic heterocycles as BET protein inhibitorsINCYTE CORP·Filed 2020·Granted Nov 15, 2022·4 cites·73 claims
- 0997US10919912B2Tricyclic heterocycles as BET protein inhibitorsINCYTE CORP·Filed 2019·Granted Feb 16, 2021·10 cites·29 claims
- 1097US10472358B21H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteinsINCYTE CORP·Filed 2018·Granted Nov 12, 2019·19 cites·30 claims
- 1197US10092570B2Heterocyclylamines as PI3K inhibitorsINCYTE CORP·Filed 2017·Granted Oct 9, 2018·17 cites·20 claims
- 1297US9957268B21H-pyrrolo[2,3,c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteinsINCYTE CORP·Filed 2016·Granted May 1, 2018·23 cites·12 claims
- 1397US9730939B2Heterocyclylamines as PI3K inhibitorsINCYTE CORP·Filed 2015·Granted Aug 15, 2017·23 cites·7 claims
- 1497US9533997B2Tricyclic heterocycles as BET protein inhibitorsINCYTE CORP·Filed 2016·Granted Jan 3, 2017·29 cites·39 claims
- 1597US9227985B2Tricyclic heterocycles as bet protein inhibitorsINCYTE CORP·Filed 2014·Granted Jan 5, 2016·40 cites·14 claims
- 1697US9096600B2N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitorsLI YUN-LONG·Filed 2011·Granted Aug 4, 2015·47 cites·28 claims
- 1797US6403632B1Lactam metalloprotease inhibitorsBRISTOL MYERS SQUIBB PHARMA CO·Filed 2000·Granted Jun 11, 2002·78 cites·18 claims
- 1896US9850257B2Tricyclic heterocycles as BET protein inhibitorsINCYTE CORP·Filed 2016·Granted Dec 26, 2017·22 cites·39 claims
- 1996US9815839B2N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitorsINCYTE CORP·Filed 2016·Granted Nov 14, 2017·20 cites·16 claims
- 2096US9527848B2N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitorsINCYTE CORP·Filed 2015·Granted Dec 27, 2016·25 cites·12 claims
- 2196US9290514B2Tricyclic heterocycles as BET protein inhibitorsINCYTE CORP·Filed 2014·Granted Mar 22, 2016·33 cites·44 claims
- 2295US11433071B2Heterocyclylamines as PI3K inhibitorsINCYTE CORP·Filed 2020·Granted Sep 6, 2022·3 cites·20 claims
- 2395US10781209B21H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteinsINCYTE CORP·Filed 2019·Granted Sep 22, 2020·12 cites·20 claims
- 2495US9944646B2Bicyclic azaheterocyclobenzylamines as PI3K inhibitorsINCYTE CORP·Filed 2016·Granted Apr 17, 2018·16 cites·22 claims
- 2594US10646492B2Heterocyclylamines as PI3K inhibitorsINCYTE CORP·Filed 2019·Granted May 12, 2020·9 cites·5 claims
- 2694US10259818B2Bicyclic azaheterocyclobenzylamines as PI3K inhibitorsINCYTE CORP·Filed 2018·Granted Apr 16, 2019·12 cites·15 claims
- 2794US9309251B2Bicyclic azaheterocyclobenzylamines as PI3K inhibitorsINCYTE CORP·Filed 2013·Granted Apr 12, 2016·25 cites·29 claims
- 2891US7101870B2Succinoylamino lactams as inhibitors of A-β protein productionBRISTOL MYERS SQUIBB PHARMA CO·Filed 2005·Granted Sep 5, 2006·13 cites·44 claims
- 2991US6962913B2Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein productionBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Nov 8, 2005·23 cites·31 claims
- 3091US6495565B2β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-αBRISTOL MYERS SQUIBB PHARMA CO·Filed 2001·Granted Dec 17, 2002·50 cites·70 claims
- 3191US2025325550A1Heterocyclylamines as pi3k inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 3289US12201636B2Heterocyclylamines as PI3K inhibitorsINCYTE CORP·Filed 2023·Granted Jan 21, 2025·0 cites·8 claims
- 3389US7304056B2Succinoylamino lactams as inhibitors of Aβ protein productionBRISTOL MYERS SQUIBB PHARMA CO·Filed 2006·Granted Dec 4, 2007·13 cites·9 claims
- 3489US7304055B2Succinoylamino lactams as inhibitors of Aβ protein productionBRISTOL MYERS SQUIBB PHARMA CO·Filed 2006·Granted Dec 4, 2007·13 cites·33 claims
- 3588US12227502B21H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c] pyridin-7(6H)-ones as inhibitors of BET proteinsINCYTE CORP·Filed 2023·Granted Feb 18, 2025·0 cites·20 claims
- 3687US5166214AUse of imidazoles for the treatment of atherosclerosisDU PONT MERCK PHARMA·Filed 1990·Granted Nov 24, 1992·41 cites·10 claims
- 3786US6794381B1Succinoylamino lactams as inhibitors of aβ proteinBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Sep 21, 2004·13 cites·22 claims
- 3886US2025289823A1Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disordersINCYTE CORP·Filed 2024·Application pending·0 cites
- 3982US6984648B2Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-αBRISTOL MYERS SQUIBB PHARMA CO·Filed 2004·Granted Jan 10, 2006·15 cites·21 claims
- 4082US6743807B2Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-αBRISTOL MYERS SQUIBB PHARMA CO·Filed 2001·Granted Jun 1, 2004·15 cites·42 claims
- 4182US6525044B2Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein productionBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Feb 25, 2003·14 cites·18 claims
- 4279US7101883B2Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinasesBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Sep 5, 2006·12 cites·18 claims
- 4379US6610731B2Lactam metalloprotease inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Aug 26, 2003·8 cites·17 claims
- 4479US5179117AAntihypercholesterolemic 2-substituted imidazolesDU PONT MERCK PHARMA·Filed 1991·Granted Jan 12, 1993·20 cites·24 claims
- 4576US2025145621A11H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINSINCYTE CORP·Filed 2025·Application pending·0 cites
- 4673US5318984AImidazoles for the treatment of atherosclerosisDU PONT MERCK PHARMA·Filed 1992·Granted Jun 7, 1994·15 cites·21 claims
- 4767US7507815B2Succinoylamino lactams as inhibitors of a-β protein productionBRISTOL MYERS SQUIBB PHARMA CO·Filed 2007·Granted Mar 24, 2009·0 cites·7 claims
- 4867US5942544Aα-branched anilines, toluenes, and analogs thereof as factor Xa inhibitorsDU PONT PHARM CO·Filed 1997·Granted Aug 24, 1999·11 cites·18 claims
- 4964US6057336ALactam metalloprotease inhibitorsDU PONT·Filed 1998·Granted May 2, 2000·22 cites·54 claims
- 5063US7125870B2Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzymeBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Oct 24, 2006·2 cites·28 claims
Showing the top 50 of 63 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →